West Pharmaceutical Services Inc. (NYSE:WST) shares reached a new 52-week high during trading on Monday . The company traded as high as $82.64 and last traded at $82.57, with a volume of 131,994 shares. The stock had previously closed at $81.56.

A number of research analysts recently commented on the company. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a report on Friday, July 22nd. Jefferies Group reaffirmed a “hold” rating on shares of West Pharmaceutical Services in a research note on Thursday, August 4th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $90.00 price objective (up previously from $69.00) on shares of West Pharmaceutical Services in a research note on Friday, May 13th.

The stock has a 50 day moving average price of $79.82 and a 200-day moving average price of $72.08. The stock has a market cap of $6.07 billion and a price-to-earnings ratio of 60.34.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 28th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.56 by $0.03. During the same period last year, the business earned $0.47 earnings per share. The company had revenue of $388 million for the quarter, compared to analyst estimates of $384.58 million. The firm’s revenue was up 7.9% on a year-over-year basis. On average, analysts expect that West Pharmaceutical Services Inc. will post $2.23 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 3rd. Investors of record on Wednesday, July 20th were issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.59%. The ex-dividend date was Monday, July 18th.

In other West Pharmaceutical Services news, VP Daniel Malone sold 3,950 shares of the stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $74.95, for a total transaction of $296,052.50. Following the transaction, the vice president now owns 30,666 shares in the company, valued at $2,298,416.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paula A. Johnson sold 3,042 shares of the stock in a transaction that occurred on Tuesday, August 23rd. The stock was sold at an average price of $81.55, for a total value of $248,075.10. Following the transaction, the director now owns 38,450 shares in the company, valued at approximately $3,135,597.50. The disclosure for this sale can be found here.

An institutional investor recently raised its position in West Pharmaceutical Services stock. Principal Financial Group Inc. raised its position in West Pharmaceutical Services Inc. (NYSE:WST) by 2.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 226,582 shares of the company’s stock after buying an additional 6,187 shares during the period. Principal Financial Group Inc. owned approximately 0.31% of West Pharmaceutical Services worth $13,645,000 as of its most recent SEC filing.

West Pharmaceutical Services, Inc is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.